{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=20",
    "query": {
      "intervention": "Placebo, Cohort 3",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 1069,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T23:07:18.827Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03334851",
      "title": "Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "PF-06835375",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 74,
      "start_date": "2017-11-17",
      "completion_date": "2022-02-15",
      "has_results": true,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 17,
      "location_summary": "Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334851"
    },
    {
      "nct_id": "NCT04078022",
      "title": "Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Shigella"
      ],
      "interventions": [
        {
          "name": "SF2a-TT15 Shigella Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "S. flexneri 2a strain 2457T Challenge Agent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 58,
      "start_date": "2020-03-02",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04078022"
    },
    {
      "nct_id": "NCT06610279",
      "title": "A Study of TAK-951 in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-951",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2022-01-07",
      "completion_date": "2023-09-21",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06610279"
    },
    {
      "nct_id": "NCT00592774",
      "title": "Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuralgia"
      ],
      "interventions": [
        {
          "name": "E2007 (perampanel)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2008-01",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 42,
      "location_summary": "Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00592774"
    },
    {
      "nct_id": "NCT03303625",
      "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Viruses",
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Ad26.RSV.preF (1*10^11 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.RSV.preF (5*10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2017-11-29",
      "completion_date": "2020-04-21",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "Newton, Kansas",
      "locations": [
        {
          "city": "Newton",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303625"
    },
    {
      "nct_id": "NCT05806359",
      "title": "A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Danicamtiv",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 33,
      "start_date": "2023-03-31",
      "completion_date": "2023-08-14",
      "has_results": false,
      "last_update_posted_date": "2024-05-23",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05806359"
    },
    {
      "nct_id": "NCT03384823",
      "title": "A Study of EDP-938 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "EDP-938",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enanta Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 90,
      "start_date": "2017-12-07",
      "completion_date": "2018-07-03",
      "has_results": false,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03384823"
    },
    {
      "nct_id": "NCT04547361",
      "title": "A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "E2511",
          "type": "DRUG"
        },
        {
          "name": "E2511 Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-14",
      "completion_date": "2021-05-26",
      "has_results": false,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04547361"
    },
    {
      "nct_id": "NCT04182490",
      "title": "LMN-101 in a Campylobacter Human Challenge Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Campylobacter Infections"
      ],
      "interventions": [
        {
          "name": "LMN-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Lumen Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-02-21",
      "completion_date": "2022-10-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04182490"
    },
    {
      "nct_id": "NCT02496143",
      "title": "A Safety and PK Study of EC-18 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chemotherapy-induced Neutropenia"
      ],
      "interventions": [
        {
          "name": "EC-18",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enzychem Lifesciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2015-07",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-11",
      "last_synced_at": "2026-10-15T23:07:18.827Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02496143"
    }
  ]
}